Compare Dover Corp (DOV) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs IDEXX Laboratories, Inc. — how do they compare? Dover Corp trades at $207.57 (market cap $28.07B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Dover Corp pays a 1.01% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| DOV | IDXX | |
|---|---|---|
Market Cap | $28.07B | $46.22B |
Sector | Industrials | Health |
52-Week High | $233.31 | $766.68 |
52-Week Low | $161.16 | $526.44 |
Enterprise Value | $29.58B | $47.12B |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $208.07, down 0.97% on the day, with strong analyst support showing 19 buy ratings and a $232.33 consensus price target. The company demonstrates solid fundamentals with consistent earnings beats, a 13.48% net income margin, and recent dividend increases. Technical indicators show a bearish short-term signal despite neutral oscillators, with key support at $205.
DOV presents a compelling investment case with strong profitability, dividend growth, and raised 2026 guidance, though near-term technical weakness and acquisition integration risks warrant monitoring. The stock offers approximately 11.7% upside to analyst targets with no sell ratings among 28 covering firms.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
